In NSCLC patients with MET exon 14-skipping mutations, an overall response was observed in 41% (95% CI 29–53) of 69 patients who were previously treated with one or two lines, and in 68% (95% CI 48–84) of 28 patients who were previously untreated. The gene discussed is MET; the disease is non-small cell lung carcinoma.